13Aug/18

FDA Grants Breakthrough Therapy Designation For Food Allergy Med

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Genentech’s,Xolair (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies.Read More…

11Jul/18

Mylan Launches Generic Version Of The Novartis Exelon Patch

Mylan N.V. today announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis’ Exelon Patch. Mylan received final approval fromRead More…

12Jun/18

FDA Approves Genentech’s Rituxan For Pemphigus Vulgaris

The U.S. Food and Drug Administration (FDA) has approved Genentech’s Rituxan (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare, serious, potentially life-threatening condition characterized by progressive painfulRead More…

16Apr/18

Lonza Opens World’s Largest Dedicated Cell And Gene Therapy Manufacturing Facility

Lonza opened the world’s largest dedicated cell and gene therapy facility, which was built in anticipation of the rising demand from developers of cell and gene therapies—believed to be the next era inRead More…

Proposed changes to nutrition labels and marketing food to children

The nutrition labels on packaged food and beverages may be due a makeover, thanks to proposals from the Food and Drug Administration. The agency is accepting public comment on the proposed changes for 90 days. If passed, the proposed changes will mark the first major overhaul for nutrition labels since the Food and Drug Administration (FDA) made them compulsory 20 years ago. (more…)